Eurasian Raging -- The Calandra Report (Tuesday July 12, Wednesday July 13, 2016)
|
By The Calandra Report
on 7/19/2016
-- Monarques Gold of Quebec received a lift after Rob McEwen and a second investor, Greg Chamandy, raised their stakes to a combined 27 percent. We discussed the Abitibi Gold Belt company briefly in a discussion with Mr. McEwen of McEwen Mining. As noted in TCR earlier in the week. MQR for Monarques ticker Canada | MUX for McEwen Mining USA, Canada ticker
--
Eurasian Minerals' drop-it price at the close earlier this week was a window for purchases. As stated, I bought in after-market at 71 cents USD. I own more than 110,000 shares of the Colorado headquartered company. The shares in largely USA trading (EMXX ticker) closed Tuesday at 82 cents with more than 1 million shares changing hands. That's 20x average trading for a second day. Why did the drop, a sharp sell-off in fast and rapid trades on the previous day, occur? Sometimes this is a scare tactic used by speculation-mongers to snag stock cheaply. (This tactic would do well to be reviewed as stringently by market regulators as the opposite: heightening hype for stock sales.) Eurasian Minerals CEO, David Cole, told me he intended to purchase more stock as of today (Tuesday).
I just learned that Eurasian Minerals, a project spawner and royalty collector of minerals properties and claims, owns or controls land and claims adjacent to or near Arizona Mining's Bronco Creek gold and zinc property in Santa Cruz County, Arizona.
The Arizona Mining geology work there (Hermosa project, polymetallic) -- along with kind words from writers -- has propelled that Canada-run company's stock market value to near $400 million CAD during a span of months. I do not own it and have no intention of purchasing AZ (ticker in Canada) shares.
As for our Eurasian Minerals, we will almost surely continue to see raging trading in shares. Expect Russia officials' clearance this summer on Eurasian's 40-odd percent stake in that far eastern Russia copper project considered "strategic" by the Kremlin. After the 7-11 EMXX scare, the shares will gain on thick trading from here through such news.
We have seen this planted scare thing happen in sizzler markets with
biomedical stocks and other "small-co" shares. It happens quickly and is coordinated.
-- I shed another 2,500 shares of Gold Standard Ventures today at a profit and still hold about 55,000 of GSV. It's a Nevada project developer.
-- Working well: Those Alamos Gold warrants FROM January are up 5-fold. I expect the same for West Kirkland Mining's tradeable warrants, which expire in 2019. ... Thank you again to Florida strategist Anthony Giallourakis; his tag of Exact Sciences (EXAS on NASDAQ) was just the right medicine for those looking for a billion-dollar stock to gambit. EXAS rose beyone $13.40 today, and yes I still own some EXAS. Other biomedicals held here at TC-TCR: BioCryst Pharma, Immunovaccine, Cellceutix (just recently on this last, OTC one -- CTIX ticker in USA).
Vienna, Austria: Founding City Of Sound Money --
Asset Protection & Investments September 18 - 24, 2016,
and TCR Network memberECI Development stages the confab each year for anyone in the First World looking to spread their ideas, assets and family to the second and third worlds.
( I am attending Freedom Fest & accompanying Anthem Film Festival this year. It is Wednesday evening through Saturday this week at Planet Hollywood in Las Vegas, Nevada. The live stream is a first this year. Many of our TCR Network will be there. )
Gold c ur r ency -- 99.9 fine. Valaurum's
certs come in quarter-gram purest gold and tenth-grams and are art-house quality for chophouse prices. I am an investor in
Valaurum, Adam Trexler's private company.
If you're balking at the rising price of gold these days, start hoarding these, in a bunch of styles. APMEX and others sell 'em.
-- Thom Calandra
These are a public service for our
TCR
audience. I receive only the satisfaction of helping to enrich our
TCR Network.
|
The Calandra Report: Subscribe
- Option 1 – pay for 1 year here
- Option 2 – recu
r s
YEARLY
here
Thom Calandra & TCR are researchers and investors. They are not registered investment advisers. The research and material they offer to subscribers are meant as editorial opinion.
|
|